Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Brief Summary: Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is examining the effect of various treatments on cardiovascular disease in people with diabetes. This current study will examine the effects of the ACCORD treatments on the progression of DR in people participating in the ACCORD study.


Options:
A: Arm Label: Intensive glycemia control; Type: EXPERIMENTAL; Interventions: Drug: Hypoglycemic Agents | Arm Label: Standard glycemia control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard glycemia control | Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP treatment | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Arm Label: Fibrate; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate, Drug: Simvastatin | Arm Label: Fibrate Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Hypoglycemic Agents; Assigned to Arm(s): Intensive glycemia control | Intervention Type: DRUG; Name: Standard glycemia control; Assigned to Arm(s): Standard glycemia control | Intervention Type: DRUG; Name: Intensive BP treatment; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): Fibrate | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Fibrate, Fibrate Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fibrate Placebo
B: Arm Label: Dapagliflozin (10 mg); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin | Arm Label: Dapagliflozin (5 mg); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin (10 mg) | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin (5 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2
D: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo

Answer: A